A study now underway on vaccine manufacturing examines the effects of focusing on consistency during manufacturing, instead of post-production testing.
The European Pharmacopoeia has incorporated new provisions that would encourage pharmaceutical manufacturers to shift focus from post-production testing, including animal testing, to the use of in-process and modern quality control methods. The goal would be to monitor consistency and variability during production. The approach is already being used for the latest generation of vaccines, and is being studied in vaccine manufacturing, in the Vaccines Consistency Approach project, which was started by the European Partnership for Alternatives to Animal Testing (EPAA), with partners from industry, academia and government agencies. A May paper discussed the methods and approach being used in this project, and some issues involved in using this approach, especially for older vaccines whose manufacturing processes may not be that well characterized. In the end, the researchers conclude, the effort must be industry-led if it is to succeed. In the U.S., the move was originally pushed by regulators, specifically FDA, in efforts such as 21st century cGMPs and the Process Analytical Technologies (PAT) initiative. Click here to read the report.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.